STOCK TITAN

Sinovac Biotech, Ltd. - SVA STOCK NEWS

Welcome to our dedicated news page for Sinovac Biotech, Ltd. (Ticker: SVA), a resource for investors and traders seeking the latest updates and insights on Sinovac Biotech, Ltd..

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Sinovac Biotech, Ltd.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Sinovac Biotech, Ltd.'s position in the market.

News
Rhea-AI Summary
Sinovac Biotech (SVA) Extends Shareholder Rights Plan Expiration Date
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Sinovac Biotech Ltd. (NASDAQ: SVA) has announced that its Board of Directors unanimously recommends shareholders not to tender their shares for purchase pursuant to the Offer to Purchase by Alternative Liquidity. The Board believes the offer price is less than the value of the company's assets and that the tender offer represents an opportunistic attempt to make a profit by purchasing shares at a very low price. The company has strong cash reserves and short-term investments, with $1.6 billion in cash and cash equivalents and restricted cash as of June 30, 2023, and $9.4 billion in short-term investments. The company also posted $14.0 million of net income attributable to common shareholders in the six-month period ended June 30, 2023. The full details of the Board's recommendation are available in the Schedule 14D-9 filed with the SEC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Summary
Sinovac Biotech completes phase I clinical trial for Anti-COVID-19 Antibody SA55 Injection and enters phase II trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial covid-19
Rhea-AI Summary
Sinovac's Board of Directors unanimously recommends shareholders reject Alternative Liquidity's tender offer of $0.03 per share in cash.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Summary
Sinovac Biotech confirms unsolicited partial tender offer from Alternative Liquidity Index LP to purchase up to 10,000,000 shares for $0.03 per share in cash.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Sinovac Biotech announces change in legal representative for subsidiary Sinovac Beijing
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Sinovac Biotech announces unaudited financial results for the first half of 2023, with sales of $140.4 million compared to $1.2 billion in the prior year period. Net income attributable to common shareholders was $14.0 million, compared to $481.6 million in the prior year period. The company is focused on increasing investment in research and development and production of vaccines beyond COVID-19, as well as exploring additional biomedical products including antibodies. Sinovac's broad-spectrum neutralizing antibody products for COVID-19 have been approved for clinical trial in China.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
covid-19
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Sinovac Biotech, Ltd.

Nasdaq:SVA

SVA Rankings

SVA Stock Data

642.44M
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
China (Mainland)
Beijing

About SVA

sinovac biotech ltd. is a china-based biopharmaceutical company that focuses on research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases including hepatitis a and b, seasonal influenza, h5n1 pandemic influenza (avian flu), h1n1 influenza (swine flu), and mumps, as well as animal rabies vaccine for canines. in 2009, sinovac was the first company worldwide to receive approval for its h1n1 influenza vaccine, panflu.1, and has manufactured it for the chinese central government, pursuant to the government-stockpiling program. the company is also the only supplier of the h5n1 pandemic influenza vaccine to the government-stockpiling program. sinovac is developing a number of new pipeline vaccines including vaccines for enterovirus 71 (against hand, foot, and mouth disease), of which the ev71 vaccine is currently in phase iii clinical trials, pneumococcal conjugate, pneumococcal polysaccharides, and rubella. sinovac sells its vaccine